Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Valuation with cash multiples

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Private equity investments in new and emerging drug companies.
Figure 2: Comparison of public and private equity market cash mulitples.
Figure 3: Venture multiples have declined since the 1990s.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Booth, B. Valuation with cash multiples. Nat Rev Drug Discov 4, 533–534 (2005). https://doi.org/10.1038/nrd1779

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1779

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing